These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38993510)

  • 1. Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study.
    Ji F; Tran S; Ogawa E; Huang CF; Suzuki T; Wong YJ; Toyoda H; Jun DW; Li L; Uojima H; Nozaki A; Chuma M; Tseng CH; Hsu YC; Ishigami M; Honda T; Atsukawa M; Haga H; Enomoto M; Trinh H; Preda CM; Vutien P; Landis C; Lee DH; Watanabe T; Takahashi H; Abe H; Asai A; Eguchi Y; Li J; Wang X; Li J; Liu J; Liang J; Lam CP; Huang R; Ye Q; Pan H; Zhang J; Cai D; Wang Q; Huang DQ; Wong G; Wong VW; Li J; Do S; Furusyo N; Nakamuta M; Nomura H; Kajiwara E; Yoon EL; Ahn SB; Azuma K; Dohmen K; An J; Song DS; Cho HC; Kawano A; Koyanagi T; Ooho A; Satoh T; Takahashi K; Yeh ML; Tsai PC; Yasuda S; Zhao Y; Liu Y; Okubo T; Itokawa N; Jun MJ; Ishikawa T; Takaguchi K; Senoh T; Zhang M; Zhao C; Alecu RI; Xuan Tay W; Devan P; Liu JK; Kozuka R; Vargas-Accarino E; Do AT; Maeda M; Chuang WL; Huang JF; Dai CY; Cheung R; Buti M; Niu J; Xie W; Ren H; Lim SG; Wu C; Yuen MF; Shang J; Zhu Q; Ueno Y; Tanaka Y; Hayashi J; Yu ML; Nguyen MH
    J Clin Transl Hepatol; 2024 Jul; 12(7):646-658. PubMed ID: 38993510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b.
    Ji F; Li J; Liu L; Liang J; Wang X; Liu J; Cai D; Huang R; Zhang J; Wang Q; Nan Y; Li J; Ye Q; Zhang M; Xu Q; Guo F; Zhao C; Liu L; He C; Li Y; Wang W; Kam LY; Tran S; Maeda M; Mizuta A; Li Z; Dang S; Ren W; Zhu Q; Cheung R; Niu J; Xie W; Pan H; Ren H; Wu C; Shang J; Wang F; Nguyen MH
    J Gastroenterol Hepatol; 2021 Mar; 36(3):767-774. PubMed ID: 32840326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
    Dietz J; Graf C; Berg CP; Port K; Deterding K; Buggisch P; Peiffer KH; Vermehren J; Dultz G; Geier A; Reiter FP; Bruns T; Schattenberg JM; Durmashkina E; Gustot T; Moreno C; Trauth J; Discher T; Fischer J; Berg T; Kremer AE; Müllhaupt B; Zeuzem S; Sarrazin C;
    JHEP Rep; 2024 Jul; 6(7):101072. PubMed ID: 39006503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
    Chen CY; Huang CF; Cheng PN; Tseng KC; Lo CC; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Kao JH; Chuang WL; Lin HC; Yu ML
    Liver Int; 2021 Jun; 41(6):1265-1277. PubMed ID: 33655714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Findings from a large Asian chronic hepatitis C real-life study.
    Lim SG; Phyo WW; Shah SR; Win KM; Hamid S; Piratvisuth T; Tan SS; Dan YY; Lee YM; Ahmed T; Yang WL; Chen KP; Kamat M; Wadhawan M; Madan K; Mehta R; Shukla A; Dhore P; Eapen CE; Abraham P; Tyagi S; Koshy A; Bwa AH; Jafri W; Abid S; Arisar FAQ; Tanwandee T; Yin TP; Tee HP; Hj Md Said RB; Goh KL; Ho SH; Mohamed R; Abu Bakar N
    J Viral Hepat; 2018 Dec; 25(12):1533-1542. PubMed ID: 30141214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
    Papaluca T; Roberts SK; Strasser SI; Stuart KA; Farrell G; MacQuillan G; Dore GJ; Wade AJ; George J; Hazeldine S; O'Beirne J; Wigg A; Fisher L; McGarity B; Sawhney R; Sinclair M; Thomas J; Valiozis I; Weltman M; Wilson M; Woodward A; Ahlenstiel G; Haque M; Levy M; Prewett E; Sievert W; Sood S; Tse E; Valaydon Z; Bowden S; Douglas M; New K; O'Keefe J; Hellard M; Doyle J; Stoove M; Thompson AJ
    Clin Infect Dis; 2021 Nov; 73(9):e3288-e3295. PubMed ID: 32887983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
    Wong YJ; Thurairajah PH; Kumar R; Tan J; Fock KM; Law NM; Li W; Kwek A; Tan YB; Koh J; Lee ZC; Kumar LS; Teo EK; Ang TL
    J Gastroenterol Hepatol; 2021 May; 36(5):1300-1308. PubMed ID: 33217040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
    Werner CR; Schwarz JM; Egetemeyr DP; Beck R; Malek NP; Lauer UM; Berg CP
    World J Gastroenterol; 2016 Sep; 22(35):8050-9. PubMed ID: 27672299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
    Lo CC; Huang CF; Cheng PN; Tseng KC; Chen CY; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Chang TS; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Chuang WL; Lin HC; Kao JH; Yu ML;
    J Formos Med Assoc; 2022 Aug; 121(8):1567-1578. PubMed ID: 35123849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
    Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
    J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
    Krishnan P; Pilot-Matias T; Schnell G; Tripathi R; Ng TI; Reisch T; Beyer J; Dekhtyar T; Irvin M; Xie W; Larsen L; Mensa FJ; Collins C
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real world experience with the all-oral interferon free regimen for the treatment of chronic hepatitis c virus infection in the Lebanese population.
    Saba J; Abou Rached A; Yaghi C; Sharara A; Ammar W
    J Infect Dev Ctries; 2018 Feb; 12(2.1):30S. PubMed ID: 31805005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study].
    Xu Q; Zhang W; Ma YX; He CN; Zhang LT; Abulitifu Y; Li Y; Wang N; Wang HL; Zhao YY; Gao X; Gao PG; Su XY; Li S; Liu YY; Guo F; Chen ZQ; Liu HL; Gao XQ; Fu JJ; Yu GY; Wang XZ; Wang JP; Zhang YP; Ji FP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Nov; 29(11):1046-1052. PubMed ID: 34933421
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care.
    Tan SS; Adlin Nadia Z
    Med J Malaysia; 2017 Jun; 72(3):165-174. PubMed ID: 28733564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
    Lawitz E; Gane E; Feld JJ; Buti M; Foster GR; Rabinovitz M; Burnevich E; Katchman H; Tomasiewicz K; Lahser F; Jackson B; Shaughnessy M; Klopfer S; Yeh WW; Robertson MN; Hanna GJ; Barr E; Platt HL;
    J Viral Hepat; 2019 Sep; 26(9):1127-1138. PubMed ID: 31108015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
    Ferenci P; Bourgeois S; Buggisch P; Norris S; Curescu M; Larrey D; Marra F; Kleine H; Dorr P; Charafeddine M; Crown E; Bondin M; Back D; Flisiak R
    J Viral Hepat; 2019 Jun; 26(6):685-696. PubMed ID: 30739368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis.
    Loo JH; Xu WXF; Low JT; Tay WX; Ang LS; Tam YC; Thurairajah PH; Kumar R; Wong YJ
    World J Hepatol; 2022 Jun; 14(6):1248-1257. PubMed ID: 35978662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.
    Zeuzem S; Bourgeois S; Greenbloom S; Buti M; Aghemo A; Lampertico P; Janczewska E; Lim SG; Moreno C; Buggisch P; Tam E; Corbett C; Willems W; Vijgen L; Fevery B; Ouwerkerk-Mahadevan S; Ackaert O; Beumont M; Kalmeijer R; Sinha R; Biermer M;
    Hepatology; 2019 Jun; 69(6):2349-2363. PubMed ID: 30693573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    Naganuma A; Chayama K; Notsumata K; Gane E; Foster GR; Wyles D; Kwo P; Crown E; Bhagat A; Mensa FJ; Otani T; Larsen L; Burroughs M; Kumada H
    J Gastroenterol; 2019 Aug; 54(8):752-761. PubMed ID: 30868245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.